Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?

Company Overview - Black Diamond (BDTX) is part of the Medical sector, which includes 932 companies and ranks 8 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for BDTX's full-year earnings has increased by 39.2%, reflecting improved analyst sentiment [4] - Year-to-date, Black Diamond has returned 9.1%, outperforming the Medical sector's average return of 8.3% [4] Industry Context - Black Diamond operates within the Medical - Biomedical and Genetics industry, which consists of 453 stocks and ranks 88 in the Zacks Industry Rank [6] - The average return for stocks in this industry is 21.9% this year, indicating that BDTX is slightly underperforming compared to its industry peers [6] Comparative Analysis - Bionano Genomics, Inc. (BNGO) is another Medical stock that has shown strong performance, with a year-to-date return of 9.2% and a consensus EPS estimate increase of 46.2% over the past three months [5] - Both Black Diamond and Bionano Genomics are noteworthy for investors interested in the Medical sector due to their solid performance [7]